Compare iShares MSCI Hong Kong ETF (EWH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 142.5× iShares MSCI Hong Kong ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Novo Nordisk A/S for 116 Days on average.
| EWH | NVO | |
|---|---|---|
Market Cap | $1.16B | $165.31B |
Volume | 3,176,523 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $63.98 |
52-Week Low | $20.66 | $35.29 |
Typical Hold Time | 61 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Empowered Funds reducing its position by 70.2% in August 2026.
The outlook remains cautious given Hong Kong market volatility and geopolitical risks. Investment opportunity exists for contrarian investors if technical oversold conditions lead to rebound, but risks include continued Hang Seng weakness and macroeconomic pressures. Wall Street sentiment appears mixed with some seeing value while others reduce exposure.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
